Actively Recruiting
Primary Aldosteronism: Prospective Screening Registry in China
Led by Shanghai Jiao Tong University School of Medicine · Updated on 2024-08-13
10000
Participants Needed
1
Research Sites
332 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
1. Study name: A prospective study of the incidence and outcomes of Primary aldosteronism in Chinese hypertensive patients 2. Rationale: Unlike essential hypertension, secondary hypertension is caused by certain defined diseases or causes. For this reason, secondary hypertension can often be cured or effectively controlled. As one of the most common types of secondary hypertension, it is estimated that primary aldosteronism (PA) accounts for 5%-10% of all hypertensive patients, accounting for about 20% of patients with refractory hypertension. 3. Objective: 1) Collect and analyze the population and disease characteristics of Chinese PA patients; 2) Strengthen the awareness of screening for PA in people with high blood pressure. 4. Study design: Prospective , multi-center, observational study. 5. Study population: Hypertensive patients with high suspected or confirmed of primary aldosteronism. 6. Treatment: Standardized diagnosis and treatment procedure as recommended in the international guidelines of PA. 7. Follow up: 6, 12 and 24 months after diagnosis. 8. Sample size estimation: About 10 thousand. 9. Timeline: Start of subjects enrollment: July 2019; End of subjects enrollment: December 2022; End of study: December 2024. 10. Organization: The Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital, Shanghai, China.
CONDITIONS
Official Title
Primary Aldosteronism: Prospective Screening Registry in China
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 65 years old
- Diagnosed with hypertension
- Plasma aldosterone renin ratio (ARR) greater than 40
- Provided informed consent to participate in the study
You will not qualify if you...
- Not eligible as determined by the investigator or not meeting inclusion criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Institite of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China, 200025
Actively Recruiting
Research Team
J
Jiguang Wang, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here